论文部分内容阅读
目的 :从分子水平研究抗纤Ⅰ号方剂治疗肝纤维化作用机理。方法 :利用CCl4 制造大鼠肝纤维化模型 ,设立正常对照组、肝纤维化模型组及中药治疗组 ,中药灌胃治疗 4 2d ,检测病理学指标、肝纤维化血清学指标、肝组织Ⅰ、Ⅲ型胶原的免疫组化 ,以及肝组织TGFβ1mRNA表达量的变化。结果 :肝组织病理学以及血清学指标同对照组统计学尚有显著差异 ,同时实验也表明治疗组能够明显减少肝组织Ⅰ、Ⅲ型胶原以及TGFβ1mRNA的表达量。结论 :抗纤Ⅰ号具有逆转肝纤维化的作用 ,其作用机理可能是通过下调TGFβ1mRNA ,抑制Ⅰ、Ⅲ型胶原的合成而减轻肝纤维化。
Objective : To study the mechanism of anti-fibrosis effect on hepatic fibrosis at the molecular level. METHODS: Rat hepatic fibrosis model was established using CCl4. Normal control group, hepatic fibrosis model group and traditional Chinese medicine treatment group were established. Herbs were intragastrically administered for 42 days. Pathological parameters, serum markers of hepatic fibrosis, and liver tissue I were determined. Immunohistochemistry of type III collagen and changes in the expression of TGFβ1 mRNA in liver tissue. RESULTS: There were significant differences between liver histopathology and serological markers in the control group, and the experiment also showed that the treatment group could significantly reduce the expression of type I and type III collagen and TGFβ1 mRNA in liver tissue. Conclusion: Anti-fibrosis I has the effect of reversing hepatic fibrosis. Its mechanism of action may be to reduce hepatic fibrosis by down-regulating TGFβ1 mRNA and inhibiting the synthesis of type I and type III collagen.